Bullfrog AI (BFRG) vs GT Biopharma (GTBP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GT Biopharma (GTBP) has outperformed Bullfrog AI (BFRG) over the past year, gaining 789.5% versus a loss of 55.6%. GT Biopharma is the larger company by market cap ($12.1 million vs $12.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRG | GTBP |
|---|---|---|
| Share price | $0.646 | $6.68 |
| Market cap | $11.98M | $12.05M |
| 1-day change | -6.70% | +12.27% |
| YTD return | -21.59% | +750.96% |
| 1-year return | -55.62% | +789.48% |
| 5-year return | — | -96.32% |
| EPS (TTM) | $-0.46 | $-161.13 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.96 | $28.75 |
| 52-week low | $0.425 | $4.91 |
| Distance from 52-week high | -67.04% | -76.77% |
| Analyst consensus | none | none |
| Avg. price target upside | — | +1022.75% |
| Average volume | 5.34M | 55.52K |
| Shares outstanding | 18.54M | 1.80M |
| Employees | 9 | 1 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GTBP has outperformed BFRG by 845.1 percentage points over the past year.
About Bullfrog AI
BFRG stock →Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
About GT Biopharma
GTBP stock →GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees
BFRG vs GTBP FAQ
Which is bigger, Bullfrog AI or GT Biopharma?
GT Biopharma (GTBP) is larger, with a market capitalization of $12.05M compared with $11.98M for Bullfrog AI (BFRG).
Which stock has performed better over the past year, BFRG or GTBP?
GTBP returned +789.48% over the past 12 months, compared with -55.62% for BFRG (price return, excluding dividends). Past performance does not predict future results.
Are Bullfrog AI and GT Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.